

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Technology Appraisal

**Artificial intelligence (AI) technologies to assist histopathology
for prostate cancer diagnosis (ID6684)**

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> • Aiforia • AIRA matrix • Deep Bio • Indica Labs • Ibex Medical Analytics • Mindpeak GmbH • Tempus • Qritive <p><u>Patient and carer groups</u></p> <ul style="list-style-type: none"> • Black Health Agency for Equality • Bob Champion cancer trust • Cancer Black Care • Everyman • Helen Rollason Cancer Charity • Independent Cancer Patients Voice • Macmillan Cancer Support • Maggie’s Centres • Marie Curie • Movember Foundation • Orchid- Fighting Male Cancer • Prostate Cancer UK • Prostate Matters • Tackle Prostate Cancer • Prost8 UK • South Asian Health Foundation • Specialised Healthcare Alliance • Tenovus Cancer Care <p><u>Healthcare professional groups</u></p> <ul style="list-style-type: none"> • Association of Cancer Physicians • Association for Clinical Biochemistry and Laboratory Medicine 	<p><u>General</u></p> <ul style="list-style-type: none"> • Allied Health Professionals Federation • Association of British Healthcare Industries • Association of Healthcare Technology Providers for Imaging, Radiotherapy and Care (AXrEM) • Board of Community Health Councils in Wales • British Healthcare Trades Association • British In Vitro Diagnostics Association (BIVDA) • Care Quality Commission • Department of Health, Social Services and Public Safety- Northern Ireland • Healthcare Improvement Scotland • HealthTech Alliance • Medicines and Healthcare products Regulatory Agency (MHRA) • National Association of Primary Care • National Screening Committee • NHS Confederation • NHS Supply Chain • NHS Wales Joint Commissioning Committee • National Pathology Imaging Cooperative (NPIC) • United Kingdom Accreditation Service (UKAS) • Welsh Cancer Network • Welsh Government <p><u>Other relevant companies</u></p> <ul style="list-style-type: none"> • Fujifilm • House Medical Consultants Ltd

Provisional stakeholder list for the evaluation of Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis (TA6684)

Issue date: March 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<ul style="list-style-type: none"> • Association of Clinical Pathologists • Association of Palliative Care Medicine of Great Britain • British Association of Urological Nurses • British Association of Urological Pathologists (BAUP) • British Association of Urological Surgeons • British Division of the International Academy of Pathology • British Geriatrics Society • British Institute of Radiology • British Lymphology Society • British Medical Association • British Psychosocial Oncology Society • British Uro-Oncology Group • Digital Pathology Association • Cancer Research UK • Institute of Biomedical Science • Northern Ireland Cancer Network • Nursing and Midwifery Council • Prostate Cancer Advisory Group (affiliated with Prostate Cancer UK) • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal College of Physicians and Surgeons of Glasgow • Royal College of Radiologists • Royal College of Surgeons of Edinburgh • Royal College of Surgeons of England • Royal Society of Medicine • Society and College of Radiographers • The Association for Cancer Surgery • UK Oncology Nursing Society • Urology Foundation <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England • NHS Digital 	<ul style="list-style-type: none"> • Leica Biosystems • Phillips • Roche Diagnostics • SAH Diagnostics • Sectra Ltd • Siemens • Sysmex <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research • Pro Cancer Research Fund • Prostate Cancer Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency <p><u>Evidence Review Group</u></p> <ul style="list-style-type: none"> • National Institute for Health Research Health Technology Assessment Programme (NETSCC) <p><u>Associated Guideline Group</u></p> <ul style="list-style-type: none"> • NICE - National Guideline Alliance (cancer, mental health, and women and children's health) • Health Technology Wales • Scottish Intercollegiate Guidelines Network

Provisional stakeholder list for the evaluation of Artificial intelligence (AI) technologies to assist histopathology for prostate cancer diagnosis (TA6684)

Issue date: March 2026

Provisional Consultees	Provisional Commentators (no right to submit or appeal)

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.